source
- Sanofi halts Nurix STAT6 degrader program two months after phase-1 startSanofi announced it is ending its collaboration with Nurix on a STAT6 degrader, just two months after the drug entered a phase-1 study. The two companies have worked together since 2019, with Sano…
- Kamau Therapeutics presents first clinical data from its updated sickle-cell gene-editing programKamau Therapeutics, a biotech company that entered the scene in 2023, has released clinical data from its reengineered sickle‑cell gene‑editing program for the first time. The disclosure marks the…